{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:34:26Z","timestamp":1791412466835,"version":"4.3.3"},"reference-count":324,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide. Its incidence has been increasing rapidly, alongside the growing epidemics of type 2 diabetes mellitus and overweight\/obesity. Global population age has also been increasing in parallel, and predictions indicate there will be more than 2 billion persons aged over 65 by the year 2050. The interplay between MASLD and other health conditions of older persons has been a focus of recent research. In this narrative review, we aim to describe its prevalence; clinical and sociodemographic associations; and outcomes for older persons, all of which are of significant importance when considering public health messaging as well as screening and counselling individual older adults.<\/jats:p>","DOI":"10.3390\/nu17132189","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:03:48Z","timestamp":1751277828000},"page":"2189","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-9669","authenticated-orcid":false,"given":"Daniel","family":"Clayton-Chubb","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne 3004, Australia"},{"name":"Department of Gastroenterology, Eastern Health, Box Hill 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-7273","authenticated-orcid":false,"given":"William W.","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-1664","authenticated-orcid":false,"given":"Peter W.","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and General Medicine, Werribee Mercy Hospital, Werribee 3030, Australia"},{"name":"Department of Aged Care and Medicine, The Royal Melbourne Hospital, Melbourne Medical School, The University of Melbourne, Parkville 3050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7811-8135","authenticated-orcid":false,"given":"Jessica A.","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-6140","authenticated-orcid":false,"given":"Karl","family":"Vaz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Lubel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne 3004, Australia"},{"name":"Department of Gastroenterology, Northern Health, Epping 3076, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6680-2303","authenticated-orcid":false,"given":"Alexander D.","family":"Hodge","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Eastern Health, Box Hill 3128, Australia"},{"name":"School of Health and Biomedical Science, RMIT University, Melbourne 3083, Australia"},{"name":"Eastern Clinical School, Monash University, Box Hill 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7039-6325","authenticated-orcid":false,"given":"Joanne","family":"Ryan","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-5129","authenticated-orcid":false,"given":"John J.","family":"McNeil","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-6069","authenticated-orcid":false,"given":"Alice J.","family":"Owen","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-6149","authenticated-orcid":false,"given":"Robyn L.","family":"Woods","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-7997","authenticated-orcid":false,"given":"Stuart K.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne 3004, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","first-page":"485","article-title":"Observations on fatty degeneration of the liver","volume":"1","author":"Addison","year":"1836","journal-title":"Guys Hosp. Rep."},{"key":"ref_2","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner","year":"1986","journal-title":"Prog. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155217","DOI":"10.1016\/j.metabol.2022.155217","article-title":"A 2022 update on the epidemiology of obesity and a call to action: As its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"133","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of Type 2 Diabetes\u2014Global Burden of Disease and Forecasted Trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0261-5614(99)80015-6","article-title":"Non-alcoholic fatty liver: Another feature of the metabolic syndrome?","volume":"18","author":"Camilo","year":"1999","journal-title":"Clin. Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstrom","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/liv.16016","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5694\/mja2.52104","article-title":"Diabetes mellitus and the progression of non-alcoholic fatty liver disease to decompensated cirrhosis: A retrospective cohort study","volume":"219","author":"Skoien","year":"2023","journal-title":"Med. J. Aust."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","article-title":"Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension","volume":"75","author":"Zhao","year":"2020","journal-title":"Hypertension"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_17","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Younossi, Z.M., Stepanova, M., Ong, J., Trimble, G., AlQahtani, S., Younossi, I., Ahmed, A., Racila, A., and Henry, L. (2021). Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin. Gastroenterol. Hepatol., 19.","DOI":"10.1016\/j.cgh.2020.05.064"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/jgh.15009","article-title":"Nonalcoholic fatty liver disease burden: Australia, 2019\u20132030","volume":"35","author":"Adams","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_28","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Ageing 2019 Highlights."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(14)60569-9","article-title":"Causes of international increases in older age life expectancy","volume":"385","author":"Mathers","year":"2015","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rahman, M.M., Rana, R., and Khanam, R. (2022). Determinants of life expectancy in most polluted countries: Exploring the effect of environmental degradation. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0262802"},{"key":"ref_31","unstructured":"World Health Organization (2023). Burden of Disease Attributable to Unsafe Drinking-Water, Sanitation and Hygiene, 2019 Update."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hao, L., Xu, X., Dupre, M.E., Guo, A., Zhang, X., Qiu, L., Zhao, Y., and Gu, D. (2020). Adequate access to healthcare and added life expectancy among older adults in China. BMC Geriatr., 20.","DOI":"10.1186\/s12877-020-01524-9"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Marques, S., Mariano, J., Mendonca, J., De Tavernier, W., Hess, M., Naegele, L., Peixeiro, F., and Martins, D. (2020). Determinants of Ageism against Older Adults: A Systematic Review. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17072560"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bcpt.13536","article-title":"Are older adults insufficiently included in clinical trials?\u2014An umbrella review","volume":"128","author":"Florisson","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ajag.13234","article-title":"International responses addressing the under-representation of older people in clinical research","volume":"42","author":"Markham","year":"2023","journal-title":"Australas. J. Ageing"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41591-023-02296-6","article-title":"Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality","volume":"29","author":"Tian","year":"2023","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clinre.2019.07.011","article-title":"The aged liver: Beyond cellular senescence","volume":"44","author":"Allaire","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.1840090222","article-title":"The effect of age upon liver volume and apparent liver blood flow in healthy man","volume":"9","author":"Wynne","year":"1989","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jceh.2014.01.003","article-title":"Association of serum bilirubin with aging and mortality","volume":"4","author":"Boland","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Clayton-Chubb, D., Majeed, A., Roberts, S.K., Schneider, H.G., Commins, I., Fitzpatrick, J., Woods, R.L., Ryan, J., Hussain, S.M., and Tan, N. (2024). Serum Transaminases And Older Adults: Distribution And Associations with All-Cause Mortality. J. Gerontol. A Biol. Sci. Med. Sci., 79.","DOI":"10.1016\/S0168-8278(24)01883-X"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrm3823","article-title":"Cellular senescence: From physiology to pathology","volume":"15","author":"Serrano","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/jsre.2002.6462","article-title":"Evaluation of the effect of age on functioning hepatocyte mass and liver blood flow using liver scintigraphy in preoperative estimations for surgical patients: Comparison with CT volumetry","volume":"106","author":"Wakabayashi","year":"2002","journal-title":"J. Surg. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/eurjpc\/zwae383","article-title":"Systematic Coronary Risk Evaluation 2 for Older Persons (SCORE2-OP): 10 years risk validation, clinical utility and potential improvement","volume":"32","author":"Belahnech","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155666","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study","volume":"147","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00464-020-07490-y","article-title":"Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients","volume":"35","author":"Ooi","year":"2021","journal-title":"Surg. Endosc."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lund, J., Saunders, C.L., Edwards, D., and Mant, J. (2021). Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: A cohort study. Open Heart, e001737.","DOI":"10.1101\/2021.03.09.21253132"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.mpmed.2016.10.008","article-title":"The physiology of ageing","volume":"45","author":"Navaratnarajah","year":"2017","journal-title":"Medicine"},{"key":"ref_49","first-page":"920","article-title":"Frailty affects the initial treatment response and time to recovery of mobility in acutely ill older adults admitted to hospital","volume":"46","author":"Hatheway","year":"2017","journal-title":"Age Ageing"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","article-title":"Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance","volume":"51","author":"Schwenzer","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","author":"Lee","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: A meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ultrasmedbio.2024.03.014","article-title":"WFUMB Guidelines\/Guidance on Liver Multiparametric Ultrasound. Part 2: Guidance on Liver Fat Quantification","volume":"50","author":"Ferraioli","year":"2024","journal-title":"Ultrasound Med. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., and Tiribelli, C. (2006). The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cgh.2016.03.034","article-title":"Development and Validation of the Framingham Steatosis Index to Identify Persons with Hepatic Steatosis","volume":"14","author":"Long","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.cgh.2020.01.020","article-title":"Dallas Steatosis Index Identifies Patients with Nonalcoholic Fatty Liver Disease","volume":"18","author":"McHenry","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wang, J., Xu, C., Xun, Y., Lu, Z., Shi, J., Yu, C., and Li, Y. (2015). ZJU index: A novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci. Rep., 5.","DOI":"10.1038\/srep16494"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","article-title":"External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study","volume":"11","author":"Koehler","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s44355-025-00021-3","article-title":"Scores to predict steatotic liver disease\u2014Correlates and outcomes in older adults","volume":"2","author":"Commins","year":"2025","journal-title":"NPJ Gut Liver"},{"key":"ref_64","unstructured":"MAFLD Consensus Statement Working Group (2025, June 01). Recommendations for the Assessment of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Primary Care: A Consensus Statement, Available online: https:\/\/www.gesa.org.au\/public\/13\/files\/Education%20%26%20Resources\/Clinical%20Practice%20Resources\/MAFLD\/MAFLD%20consensus%20statement%202024.pdf."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3945\/ajcn.113.068122","article-title":"BMI and all-cause mortality in older adults: A meta-analysis","volume":"99","author":"Winter","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.ijo.0800741","article-title":"Body mass index and percent body fat: A meta analysis among different ethnic groups","volume":"22","author":"Deurenberg","year":"1998","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2213-8587(21)00088-7","article-title":"Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: A population-based cohort study","volume":"9","author":"Caleyachetty","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cgh.2011.10.014","article-title":"Serum levels of alanine aminotransferase decrease with age in longitudinal analysis","volume":"10","author":"Dong","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis","volume":"71","author":"Mozes","year":"2021","journal-title":"Gut"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Mallet","year":"2007","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Forlano, R., Stanic, T., Jayawardana, S., Mullish, B.H., Yee, M., Mossialos, E., Goldin, R.D., Petta, S., Tsochatzis, E., and Thursz, M.R. (2024). Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0307500"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population with Metabolic Dysfunction","volume":"167","author":"Francque","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care","volume":"77","author":"Sripongpun","year":"2023","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2123923","DOI":"10.1001\/jamanetworkopen.2021.23923","article-title":"Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients with Nonalcoholic Fatty Liver Disease","volume":"4","author":"Younossi","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_82","first-page":"377","article-title":"Disease Progression-Related Markers for Aged Non-Alcoholic Fatty Liver Disease Patients","volume":"77","author":"Morimoto","year":"2023","journal-title":"Acta Med. Okayama"},{"key":"ref_83","first-page":"e0075","article-title":"The Steatosis-associated fibrosis estimator (SAFE) score: Validation in the general US population","volume":"7","author":"Ayada","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Pitisuttithum, P., Chan, W.K., Piyachaturawat, P., Imajo, K., Nakajima, A., Seki, Y., Kasama, K., Kakizaki, S., Fan, J.G., and Song, M.J. (2020). Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: The GOASIA study. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01240-z"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Tamaki, N., Takaura, K., Higuchi, M., Yasui, Y., Itakura, J., Tsuchiya, K., Nakanishi, H., Izumi, N., and Kurosaki, M. (2024). Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14131317"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cca.2016.08.006","article-title":"Enhanced liver fibrosis (ELF) score: Analytical performance and distribution range in a large cohort of blood donors","volume":"461","author":"Dellavance","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000065253","article-title":"Nutritional markers, acute phase reactants and tissue inhibitor of matrix metalloproteinase 1 in elderly patients with pressure sores","volume":"48","author":"Perier","year":"2002","journal-title":"Gerontology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/00365513.2021.2001045","article-title":"Reference interval for type III procollagen (PIIINP) using the Advia centaur PIIINP assay in adults and elderly","volume":"81","author":"Samyn","year":"2021","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2014.106260","article-title":"Platelet count and aging","volume":"99","author":"Balduini","year":"2014","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2016.0109","article-title":"Genetic predisposition in nonalcoholic fatty liver disease","volume":"23","author":"Sookoian","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Driessen, S., Francque, S.M., Anker, S.D., Castro Cabezas, M., Grobbee, D.E., Tushuizen, M.E., and Holleboom, A.G. (2023). Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology.","DOI":"10.1097\/HEP.0000000000000735"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr. Diab. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2007.06.020","article-title":"Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study","volume":"47","author":"Goldsmith","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e3887","DOI":"10.1097\/MD.0000000000003887","article-title":"Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern","volume":"95","author":"Wehmeyer","year":"2016","journal-title":"Medicine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","article-title":"High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance","volume":"68","author":"Webb","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chen, H., Wang, J., Li, Z., Lam, C.W.K., Xiao, Y., Wu, Q., and Zhang, W. (2019). Consumption of Sugar-Sweetened Beverages Has a Dose-Dependent Effect on the Risk of Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Dose-Response Meta-Analysis. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16122192"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/hep.22525","article-title":"Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study","volume":"48","author":"Goldsmith","year":"2008","journal-title":"Hepatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/apt.12038","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: A population-based study","volume":"36","author":"Gerber","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1249\/MSS.0000000000001901","article-title":"Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat","volume":"51","author":"Sprung","year":"2019","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"117469","DOI":"10.1016\/j.ecoenv.2024.117469","article-title":"Air pollution exposure and prevalence of non-alcoholic fatty liver disease and related cirrhosis: A systematic review and meta-analysis","volume":"289","author":"He","year":"2025","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e8491","DOI":"10.1097\/MD.0000000000008491","article-title":"Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: A meta-analysis of prospective cohort studies","volume":"96","author":"Ju","year":"2017","journal-title":"Medicine"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Sun, F., Norman, I.J., and While, A.E. (2013). Physical activity in older people: A systematic review. BMC Public Health, 13.","DOI":"10.1186\/1471-2458-13-449"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e221880","DOI":"10.1001\/jamanetworkopen.2022.1880","article-title":"Trends in Diet Quality Among Older US Adults From 2001 to 2018","volume":"5","author":"Long","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"101600","DOI":"10.1016\/j.arr.2022.101600","article-title":"Past, present and future influences of diet among older adults\u2014A scoping review","volume":"77","author":"Govindaraju","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ageing\/afh089","article-title":"Why older people do not participate in leisure time physical activity: A survey of activity levels, beliefs and deterrents","volume":"33","author":"Crombie","year":"2004","journal-title":"Age Ageing"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1519\/JPT.0b013e31820e0e71","article-title":"Motivators, barriers, and beliefs regarding physical activity in an older adult population","volume":"34","author":"Costello","year":"2011","journal-title":"J. Geriatr. Phys. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1017\/S0144686X1900076X","article-title":"Factors influencing physical activity participation among older people with low activity levels","volume":"40","author":"Rai","year":"2019","journal-title":"Ageing Soc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"l251","DOI":"10.1136\/bmj.l251","article-title":"Social determinants and non-communicable diseases: Time for integrated action","volume":"364","author":"Marmot","year":"2019","journal-title":"BMJ"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurpub\/ckw222","article-title":"The socioeconomic distribution of non-communicable diseases in Europe: Findings from the European Social Survey (2014) special module on the social determinants of health","volume":"27","author":"McNamara","year":"2017","journal-title":"Eur. J. Public Health"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.amjms.2016.01.008","article-title":"Influence of Race, Ethnicity and Social Determinants of Health on Diabetes Outcomes","volume":"351","author":"Walker","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(09)60914-4","article-title":"Indigenous health part 1: Determinants and disease patterns","volume":"374","author":"Gracey","year":"2009","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1440-1584.2008.00953.x","article-title":"Addressing the health disadvantage of rural populations: How does epidemiological evidence inform rural health policies and research?","volume":"16","author":"Smith","year":"2008","journal-title":"Aust. J. Rural. Health"},{"key":"ref_121","first-page":"7726","article-title":"Regional health inequalities in Australia and social determinants of health: Analysis of trends and distribution by remoteness","volume":"24","author":"Flavel","year":"2024","journal-title":"Rural. Remote Health"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Czapla, B.C., Dalvi, A., Hu, J., Moran, I.J., Wijarnpreecha, K., and Chen, V.L. (2025). Physical activity, diet, and social determinants of health associate with health related quality of life and fibrosis in MASLD. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-93082-6"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/liv.15725","article-title":"Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage","volume":"44","author":"Kemp","year":"2024","journal-title":"Liver Int."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kim, R.G., Ballantyne, A., Conroy, M.B., Price, J.C., and Inadomi, J.M. (2024). Screening for social determinants of health among populations at risk for MASLD: A scoping review. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1332870"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s11357-024-01435-2","article-title":"Associations between MASLD, atrial fibrillation, cardiovascular events, mortality and aspirin use in older adults","volume":"47","author":"Roberts","year":"2024","journal-title":"Geroscience"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11357-021-00486-z","article-title":"Cardiovascular risk prediction in healthy older people","volume":"44","author":"Neumann","year":"2022","journal-title":"Geroscience"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Liu, Y., Zhong, G.C., Tan, H.Y., Hao, F.B., and Hu, J.J. (2019). Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: A meta-analysis. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-47687-3"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2016.12.020","article-title":"PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease","volume":"152","author":"Simons","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2022.05.030","article-title":"Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study","volume":"77","author":"Lu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1872-034X.2011.00915.x","article-title":"Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients","volume":"42","author":"Arase","year":"2012","journal-title":"Hepatol. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"458","DOI":"10.14309\/ajg.0000000000001122","article-title":"ACG Clinical Guidelines: Colorectal Cancer Screening 2021","volume":"116","author":"Shaukat","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1053\/j.gastro.2023.06.033","article-title":"AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review","volume":"165","author":"Issaka","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Clayton-Chubb, D., Kemp, W.W., Majeed, A., Woods, R.L., Ryan, J., Murray, A.M., Chong, T.T.J., Lubel, J.S., Tran, C., and Hodge, A.D. (2024). Late-Life Metabolic Dysfunction-Associated Steatotic Liver Disease and its Association with Physical Disability and Dementia. J. Gerontol. A Biol. Sci. Med. Sci., 79.","DOI":"10.1093\/gerona\/glae011"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s44355-025-00024-0","article-title":"Steatotic liver disease is a marker of multimorbidity, not underlying cirrhosis, in older adults","volume":"2","author":"Oduwole","year":"2025","journal-title":"NPJ Gut Liver"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-020-0153-5","article-title":"Colonic diverticular disease","volume":"6","author":"Tursi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.gastro.2009.01.015","article-title":"Burden of digestive diseases in the United States part II: Lower gastrointestinal diseases","volume":"136","author":"Everhart","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"274","DOI":"10.15403\/jgld-3308","article-title":"The Interrelationship Among Non-Alcoholic Fatty Liver Disease, Colonic Diverticulosis and Metabolic Syndrome","volume":"30","author":"Milovanovic","year":"2021","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Pantic, I., Lugonja, S., Rajovic, N., Dumic, I., and Milovanovic, T. (2021). Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection?. Medicina, 58.","DOI":"10.3390\/medicina58010038"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/MCG.0000000000000267","article-title":"Visceral Abdominal Obesity Measured by Computed Tomography is Associated with Increased Risk of Colonic Diverticulosis","volume":"49","author":"Nagata","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.dld.2017.12.014","article-title":"Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease","volume":"50","author":"Kim","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Clayton-Chubb, D., Kemp, W., Majeed, A., Lubel, J.S., Hodge, A., and Roberts, S.K. (2023). Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients, 15.","DOI":"10.3390\/nu15030687"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Gupta, H., Min, B.H., Ganesan, R., Gebru, Y.A., Sharma, S.P., Park, E., Won, S.M., Jeong, J.J., Lee, S.B., and Cha, M.G. (2022). Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030550"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mib.2015.11.003","article-title":"Infection in an aging population","volume":"29","author":"Kline","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Dorrington, M.G., and Bowdish, D.M. (2013). Immunosenescence and novel vaccination strategies for the elderly. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00171"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11357-011-9371-9","article-title":"Mechanistic insights into the impairment of memory B cells and antibody production in the elderly","volume":"35","author":"Aberle","year":"2013","journal-title":"Age"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e16101","DOI":"10.1111\/liv.16101","article-title":"Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.cgh.2023.05.013","article-title":"Risk of Severe Infection in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease\u2014A Population-based Cohort Study","volume":"21","author":"Ebrahimi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Krznaric, J., and Vince, A. (2022). The Role of Non-Alcoholic Fatty Liver Disease in Infections. Life, 12.","DOI":"10.3390\/life12122052"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: The role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Cubero","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3945\/an.115.010207","article-title":"Impact of Obesity and Metabolic Syndrome on Immunity","volume":"7","author":"Andersen","year":"2016","journal-title":"Adv. Nutr."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41419-023-06146-8","article-title":"Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis","volume":"14","author":"Sim","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Spinelli, R., Baboota, R.K., Gogg, S., Beguinot, F., Bluher, M., Nerstedt, A., and Smith, U. (2023). Increased cell senescence in human metabolic disorders. J. Clin. Investig., e169922.","DOI":"10.1172\/JCI169922"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jhep.2023.01.031","article-title":"Current treatment strategies and future possibilities for sarcopenia in cirrhosis","volume":"78","author":"Ebadi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3748\/wjg.v23.i5.899","article-title":"Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist","volume":"23","author":"Sinclair","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2020.03.029","article-title":"Changes in frailty are associated with waitlist mortality in patients with cirrhosis","volume":"73","author":"Lai","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2024.08.024","article-title":"Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases","volume":"82","author":"Zhong","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"103187","DOI":"10.1016\/j.dsx.2025.103187","article-title":"The relationship between nonalcoholic fatty liver disease and frailty: A systematic review and meta-analysis","volume":"19","author":"Khanmohammadi","year":"2025","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e000861","DOI":"10.1136\/bmjgast-2021-000861","article-title":"Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease","volume":"9","author":"Naimimohasses","year":"2022","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"105845","DOI":"10.1016\/j.archger.2025.105845","article-title":"Associations of Metabolic Dysfunction-Related Fatty Liver Disease and Dementia risk: A Prospective Study Based on the UK Biobank","volume":"135","author":"Geng","year":"2025","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"George, E.S., Sood, S., Daly, R.M., and Tan, S.Y. (2022). Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic review. BMC Geriatr., 22.","DOI":"10.1186\/s12877-021-02721-w"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaneurol.2017.3229","article-title":"Association of Nonalcoholic Fatty Liver Disease with Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study","volume":"75","author":"Weinstein","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1212\/WNL.0000000000200853","article-title":"Nonalcoholic Fatty Liver Disease and Risk of Dementia: A Population-Based Cohort Study","volume":"99","author":"Shang","year":"2022","journal-title":"Neurology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jpsychires.2023.03.041","article-title":"NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis","volume":"161","author":"Huang","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1212\/WNL.0000000000200770","article-title":"Association of Nonalcoholic Fatty Liver Disease and Fibrosis with Incident Dementia and Cognition: The Rotterdam Study","volume":"99","author":"Xiao","year":"2022","journal-title":"Neurology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/archneur.63.9.1312","article-title":"Accelerated weight loss may precede diagnosis in Alzheimer disease","volume":"63","author":"Johnson","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jalz.2017.09.016","article-title":"Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals","volume":"14","author":"Kivimaki","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Watson, R., Sanson-Fisher, R., Bryant, J., and Mansfield, E. (2023). Dementia is the second most feared condition among Australian health service consumers: Results of a cross-sectional survey. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15772-y"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.archger.2017.02.013","article-title":"Concern about developing Alzheimer\u2019s disease or dementia and intention to be screened: An analysis of national survey data","volume":"71","author":"Tang","year":"2017","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1017\/S1041610219002229","article-title":"Persistent barriers and facilitators to seeking help for a dementia diagnosis: A systematic review of 30 years of the perspectives of carers and people with dementia","volume":"32","author":"Parker","year":"2020","journal-title":"Int. Psychogeriatr."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/13698570903509497","article-title":"Dementia screening and early diagnosis: The case for and against","volume":"12","author":"Milne","year":"2010","journal-title":"Health Risk Soc."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Martin, S., Kelly, S., Khan, A., Cullum, S., Dening, T., Rait, G., Fox, C., Katona, C., Cosco, T., and Brayne, C. (2015). Attitudes and preferences towards screening for dementia: A systematic review of the literature. BMC Geriatr., 15.","DOI":"10.1186\/s12877-015-0064-6"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2018-318212","article-title":"Models for predicting risk of dementia: A systematic review","volume":"90","author":"Hou","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1572-0241.2008.02034.x","article-title":"Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study","volume":"103","author":"Dunn","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","article-title":"Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease","volume":"49","author":"Ong","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.32635","article-title":"Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study","volume":"77","author":"Sonneveld","year":"2023","journal-title":"Hepatology"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Golabi, P., Paik, J., Reddy, R., Bugianesi, E., Trimble, G., and Younossi, Z.M. (2019). Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol., 19.","DOI":"10.1186\/s12876-019-0972-6"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10654-023-01094-1","article-title":"The Rotterdam Study. Design update and major findings between 2020 and 2024","volume":"39","author":"Ikram","year":"2024","journal-title":"Eur. J. Epidemiol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/liv.15629","article-title":"Genetic risk of fatty liver disease and mortality in the general population: A Mendelian randomization study","volume":"43","author":"Nordestgaard","year":"2023","journal-title":"Liver Int."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Kim, H.Y., and Rinella, M.E. (2025). Emerging Therapies and Real-World Application of Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment. Clin. Mol. Hepatol.","DOI":"10.3350\/cmh.2025.0083"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Dobbie, L.J., Burgess, J., Hamid, A., Nevitt, S.J., Hydes, T.J., Alam, U., and Cuthbertson, D.J. (2024). Effect of a Low-Calorie Dietary Intervention on Liver Health and Body Weight in Adults with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Overweight\/Obesity: A Systematic Review and Meta-Analysis. Nutrients, 16.","DOI":"10.3390\/nu16071030"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/liv.14818","article-title":"Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial","volume":"41","author":"Cantero","year":"2021","journal-title":"Liver Int."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e233513","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.clnesp.2022.03.020","article-title":"Understanding weight regain after a nutritional weight loss intervention: Systematic review and meta-analysis","volume":"49","author":"Machado","year":"2022","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s40519-023-01628-2","article-title":"Risk of binge eating disorder in patients with metabolic dysfunction-associated steatotic liver disease","volume":"28","author":"Brodosi","year":"2023","journal-title":"Eat. Weight. Disord."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e237482","DOI":"10.1001\/jamanetworkopen.2023.7482","article-title":"Associations of Change in Body Size with All-Cause and Cause-Specific Mortality Among Healthy Older Adults","volume":"6","author":"Hussain","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_196","unstructured":"Keys, A., and Keys, M. (1975). How to Eat Well and Stay Well the Mediterranean Way, Doubleday."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3934\/publichealth.2023040","article-title":"Mediterranean diet and health in the elderly","volume":"10","author":"Giuffre","year":"2023","journal-title":"AIMS Public Health"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.15363","article-title":"Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"36","author":"Mansoori","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Commins, I., Clayton-Chubb, D., Fitzpatrick, J.A., George, E.S., Schneider, H.G., Phyo, A.Z.Z., Majeed, A., Janko, N., Vaughan, N., and Woods, R.L. (2025). Associations Between MASLD, Ultra-Processed Food and a Mediterranean Dietary Pattern in Older Adults. Nutrients, 17.","DOI":"10.3390\/nu17091415"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad Libitum Mediterranean and Low-Fat Diets both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial","volume":"70","author":"Rinott","year":"2021","journal-title":"Gut"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Cueto-Gal\u00e1n, R., Fontalba-Navas, A., Guti\u00e9rrez-Bedmar, M., Ruiz-Canela, M., Mart\u00ednez-Gonz\u00e1lez, M.A., Alves, L., Babio, N., Fit\u00f3, M., Ros, E., and Fiol, M. (2025). Adherence to the Mediterranean diet to prevent or delay hepatic steatosis: A longitudinal analysis within the PREDIMED study. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1518082"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Oh, J.H., Yoon, E.L., Park, H., Lee, S., Jo, A.J., Cho, S., Kwon, E., Nah, E.H., Lee, J.H., and Park, J.H. (2025). Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease. J. Hepatol.","DOI":"10.1016\/j.jhep.2025.06.005"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet\u2014A randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Clayton-Chubb, D., Vaughan, N.V., George, E.S., Chan, A.T., Roberts, S.K., Ryan, J., Phyo, A.Z.Z., McNeil, J.J., Beilin, L.J., and Tran, C. (2024). Mediterranean Diet and Ultra-Processed Food Intake in Older Australian Adults-Associations with Frailty and Cardiometabolic Conditions. Nutrients, 16.","DOI":"10.3390\/nu16172978"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"74","DOI":"10.14283\/jfa.2019.44","article-title":"Reported Weight Change in Older Adults and Presence of Frailty","volume":"9","author":"Crow","year":"2020","journal-title":"J. Frailty Aging"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12603-017-0971-7","article-title":"Editorial: Weight Loss is a Major Cause of Frailty","volume":"21","author":"Morley","year":"2017","journal-title":"J. Nutr. Health Aging"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa1008234","article-title":"Weight loss, exercise, or both and physical function in obese older adults","volume":"364","author":"Villareal","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jamda.2014.06.013","article-title":"Mediterranean diet and risk of frailty in community-dwelling older adults","volume":"15","year":"2014","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3945\/jn.112.165498","article-title":"A higher adherence to a Mediterranean-style diet is inversely associated with the development of frailty in community-dwelling elderly men and women","volume":"142","author":"Talegawkar","year":"2012","journal-title":"J. Nutr."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1017\/S0007114518002593","article-title":"Mediterranean diet and its components in relation to all-cause mortality: Meta-analysis","volume":"120","author":"Eleftheriou","year":"2018","journal-title":"Br. J. Nutr."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Govindaraju, T., Sahle, B.W., McCaffrey, T.A., McNeil, J.J., and Owen, A.J. (2018). Dietary Patterns and Quality of Life in Older Adults: A Systematic Review. Nutrients, 10.","DOI":"10.3390\/nu10080971"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00394-017-1582-0","article-title":"Mediterranean diet and cardiovascular disease: A systematic review and meta-analysis of observational studies","volume":"58","author":"Rosato","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/CIRCRESAHA.118.313348","article-title":"The Mediterranean Diet and Cardiovascular Health","volume":"124","author":"Gea","year":"2019","journal-title":"Circ. Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/jgs.15736","article-title":"Food Insecurity: A Key Social Determinant of Health for Older Adults","volume":"67","author":"Pooler","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jgs.16971","article-title":"Food Insecurity Among Older Adults: 10-Year National Trends and Associations with Diet Quality","volume":"69","author":"Leung","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jn\/nxz212","article-title":"Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States","volume":"150","author":"Golovaty","year":"2020","journal-title":"J. Nutr."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"101597","DOI":"10.1016\/j.arr.2022.101597","article-title":"Psychosocial factors influencing the eating behaviours of older adults: A systematic review","volume":"77","author":"Walasek","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Tsofliou, F., Vlachos, D., Hughes, C., and Appleton, K.M. (2022). Barriers and Facilitators Associated with the Adoption of and Adherence to a Mediterranean Style Diet in Adults: A Systematic Review of Published Observational and Qualitative Studies. Nutrients, 14.","DOI":"10.3390\/nu14204314"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s41999-023-00774-1","article-title":"Exploring barriers and facilitators of behavioural changes in dietary intake and physical activity: A qualitative study in older adults undergoing transcatheter aortic valve implantation","volume":"14","author":"Dolman","year":"2023","journal-title":"Eur. Geriatr. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"200127","DOI":"10.1016\/j.hnm.2021.200127","article-title":"Barriers to healthy lifestyle behaviours and adherence to physical activity and dietary guidelines by older Australians: A descriptive analysis","volume":"25","author":"Gadowski","year":"2021","journal-title":"Hum. Nutr. Metab."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Sam-Yellowe, T.Y. (2024). Nutritional Barriers to the Adherence to the Mediterranean Diet in Non-Mediterranean Populations. Foods, 13.","DOI":"10.20944\/preprints202404.1733.v1"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.31158","article-title":"Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease","volume":"72","author":"Kim","year":"2020","journal-title":"Hepatology"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/flgastro-2014-100432","article-title":"Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls","volume":"6","author":"Hallsworth","year":"2015","journal-title":"Frontline Gastroenterol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/bjsports-2012-092038","article-title":"The importance of non-exercise physical activity for cardiovascular health and longevity","volume":"48","author":"Ekblom","year":"2014","journal-title":"Br. J. Sports Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.amepre.2014.05.044","article-title":"Non-exercise physical activity and survival: English longitudinal study of ageing","volume":"47","author":"Hamer","year":"2014","journal-title":"Am. J. Prev. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cgh.2020.07.023","article-title":"Physical Activity, Measured Objectively, Is Associated with Lower Mortality in Patients with Nonalcoholic Fatty Liver Disease","volume":"19","author":"Kim","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/clinem\/dgab795","article-title":"The Effect of High-intensity Interval Training vs. Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis","volume":"107","author":"Sabag","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/liv.13332","article-title":"The preventive effect of sustained physical activity on incident nonalcoholic fatty liver disease","volume":"37","author":"Kwak","year":"2017","journal-title":"Liver Int."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Babu, A.F., Csader, S., Lok, J., Gomez-Gallego, C., Hanhineva, K., El-Nezami, H., and Schwab, U. (2021). Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. Nutrients, 13.","DOI":"10.3390\/nu13093135"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The Physical Activity Guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"ref_234","unstructured":"Australian Government Department of Health and Aged Care (2025, April 28). Physical Activity and Exercise Guidelines for All Australians, Available online: https:\/\/www.health.gov.au\/topics\/physical-activity-and-exercise\/physical-activity-and-exercise-guidelines-for-all-australians."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"E728","DOI":"10.9778\/cmajo.20200222","article-title":"Effectiveness of physical activity interventions in older adults with frailty or prefrailty: A systematic review and meta-analysis","volume":"9","author":"Racey","year":"2021","journal-title":"CMAJ Open"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.archger.2018.02.005","article-title":"Physical activity combined with resistance training reduces symptoms of frailty in older adults: A randomized controlled trial","volume":"76","author":"Nagai","year":"2018","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/jech-2023-220518","article-title":"Impact of lifestyle risk factors on admission to nursing home care: A cohort study of 127 108 people aged 60 years and over","volume":"77","author":"Gibson","year":"2023","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.jhepr.2023.100963","article-title":"Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease","volume":"6","author":"Henin","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Sardeli, A.V., Komatsu, T.R., Mori, M.A., Gaspari, A.F., and Chacon-Mikahil, M.P.T. (2018). Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients, 10.","DOI":"10.3390\/nu10040423"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"e2441380","DOI":"10.1001\/jamanetworkopen.2024.41380","article-title":"Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management","volume":"7","author":"Lin","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: An individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ajcn\/74.5.579","article-title":"Long-term weight-loss maintenance: A meta-analysis of US studies","volume":"74","author":"Anderson","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"101363","DOI":"10.1016\/j.jhepr.2025.101363","article-title":"Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD","volume":"7","author":"Moolla","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Lawitz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.cgh.2021.07.010","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients with Cirrhosis and Diabetes","volume":"20","author":"Simon","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2023.06.004","article-title":"Glucagon-like Peptide-1 Receptor Agonist Use in Patients with Liver Cirrhosis and Type 2 Diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/joim.13751","article-title":"Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework","volume":"295","author":"Yang","year":"2024","journal-title":"J. Intern. Med."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: From single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"108737","DOI":"10.1016\/j.diabres.2021.108737","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis","volume":"174","author":"Karagiannis","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Berg, S., Stickle, H., Rose, S.J., and Nemec, E.C. (2025). Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes. Rev., e13929.","DOI":"10.1111\/obr.13929"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"155835","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Suvarna, R., Shetty, S., and Pappachan, J.M. (2024). Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-beta agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-70242-8"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated with Improvement of Quality of Life","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"e12948","DOI":"10.1111\/jne.12948","article-title":"The relation between thyroid dysregulation and impaired cognition\/behaviour: An integrative review","volume":"33","author":"Sajjadi","year":"2021","journal-title":"J. Neuroendocrinol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"100132","DOI":"10.1016\/j.endmts.2023.100132","article-title":"Age-related thyroid hormone resistance: A friend or foe","volume":"11","author":"Mooradian","year":"2023","journal-title":"Endocr. Metab. Sci."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2217\/pgs.09.82","article-title":"Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies","volume":"10","author":"Daily","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/dmd.118.084665","article-title":"Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans","volume":"47","author":"Itkonen","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"Delara, M., Murray, L., Jafari, B., Bahji, A., Goodarzi, Z., Kirkham, J., Chowdhury, M., and Seitz, D.P. (2022). Prevalence and factors associated with polypharmacy: A systematic review and Meta-analysis. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03279-x"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cen.12134","article-title":"Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status","volume":"80","author":"Lee","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J.R., Tam, A., Duan, W., Kerns, K., Sousa, E., and He, T. (2018). Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-22456-w"},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Bailey, N.N., Peterson, S.J., Parikh, M.A., Jackson, K.A., and Frishman, W.H. (2023). Pegozafermin Is a Potential Master Therapeutic Regulator in Metabolic Disorders: A Review. Cardiol. Rev.","DOI":"10.1097\/CRD.0000000000000625"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0168-8278(24)00437-9","article-title":"LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)","volume":"80","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination with a GLP-1 Receptor Agonist in Patients with NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cgh.2024.05.021","article-title":"Combination Treatment in MASLD: The Next Frontier","volume":"23","author":"Tsochatzis","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/liv.13185","article-title":"Nonalcoholic fatty liver disease: Cause or consequence of type 2 diabetes?","volume":"36","author":"Valenti","year":"2016","journal-title":"Liver Int."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis","volume":"96","author":"Dai","year":"2017","journal-title":"Medicine"},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Marcuccilli, M., and Chonchol, M. (2016). NAFLD and Chronic Kidney Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040562"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Rodgers, J.L., Jones, J., Bolleddu, S.I., Vanthenapalli, S., Rodgers, L.E., Shah, K., Karia, K., and Panguluri, S.K. (2019). Cardiovascular Risks Associated with Gender and Aging. J. Cardiovasc. Dev. Dis., 6.","DOI":"10.3390\/jcdd6020019"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and Functional Changes with the Aging Kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: An update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","article-title":"Under-prescription of statins in patients with non-alcoholic fatty liver disease","volume":"27","author":"Baratta","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.metabol.2015.07.003","article-title":"Nonalcoholic fatty liver disease and statins","volume":"64","author":"Tziomalos","year":"2015","journal-title":"Metabolism"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bcp.14943","article-title":"Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis","volume":"88","author":"Pastori","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study","volume":"116","author":"Lee","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_296","doi-asserted-by":"crossref","unstructured":"Laakso, M., and Fernandes Silva, L. (2023). Statins and risk of type 2 diabetes: Mechanism and clinical implications. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1239335"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"k3359","DOI":"10.1136\/bmj.k3359","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: Retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"e036357","DOI":"10.1161\/JAHA.124.036357","article-title":"Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability-Free Survival in Older People","volume":"13","author":"Zoungas","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of Aspirin on Disability-free Survival in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2213-8587(23)00327-3","article-title":"Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: A post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial","volume":"12","author":"Zoungas","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily Aspirin Use Associated with Reduced Risk For Fibrosis Progression in Patients with Nonalcoholic Fatty Liver Disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease without Cirrhosis: A Randomized Clinical Trial","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep4.1640","article-title":"Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume":"5","author":"Memel","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"102065","DOI":"10.1016\/j.eclinm.2023.102065","article-title":"Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: A population-based cohort study","volume":"61","author":"Lee","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gutjnl-2020-321585","article-title":"Major GI bleeding in older persons using aspirin: Incidence and risk factors in the ASPREE randomised controlled trial","volume":"70","author":"Mahady","year":"2021","journal-title":"Gut"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr. Diab. Rep."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_311","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., and Targher, G. (2020). Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 11.","DOI":"10.3390\/metabo11010022"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants with Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: A nationwide database study in Japan","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"106396","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: The SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"101419","DOI":"10.1016\/j.diabet.2023.101419","article-title":"Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit\/risk balance?","volume":"49","author":"Scheen","year":"2023","journal-title":"Diabetes Metab."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s41999-023-00752-7","article-title":"Diuretics, SGLT2 inhibitors and falls in older heart failure patients: To prescribe or to deprescribe? A clinical review","volume":"14","author":"Handoko","year":"2023","journal-title":"Eur. Geriatr. Med."},{"key":"ref_318","doi-asserted-by":"crossref","unstructured":"Suzuki, Y., Suzuki, H., Maruo, K., Matsuda, T., Murayama, Y., Sugano, Y., Osaki, Y., Iwasaki, H., Sekiya, M., and Hada, Y. (2025). Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-91101-0"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/CEOR.S472446","article-title":"Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives","volume":"16","author":"Torre","year":"2024","journal-title":"Clinicoecon Outcomes Res."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"224","DOI":"10.37268\/mjphm\/vol.20\/no.2\/art.304","article-title":"The economic burden of frailty among elderly people: A review of the current literature","volume":"20","author":"Alkhodary","year":"2020","journal-title":"Malays. J. Public Health Med."},{"key":"ref_322","doi-asserted-by":"crossref","unstructured":"Bock, J.O., Konig, H.H., Brenner, H., Haefeli, W.E., Quinzler, R., Matschinger, H., Saum, K.U., Schottker, B., and Heider, D. (2016). Associations of frailty with health care costs--results of the ESTHER cohort study. BMC Health Serv. Res., 16.","DOI":"10.1186\/s12913-016-1360-3"},{"key":"ref_323","doi-asserted-by":"crossref","unstructured":"Alvarez-Bustos, A., Rodriguez-Sanchez, B., Carnicero-Carreno, J.A., Sepulveda-Loyola, W., Garcia-Garcia, F.J., and Rodriguez-Manas, L. (2022). Healthcare cost expenditures associated to frailty and sarcopenia. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03439-z"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jhep.2025.01.009","article-title":"Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States","volume":"83","author":"Wallace","year":"2025","journal-title":"J. Hepatol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/13\/2189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:14Z","timestamp":1760032934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/13\/2189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":324,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["nu17132189"],"URL":"https:\/\/doi.org\/10.3390\/nu17132189","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}